Rosen Law Firm is reminding investors who purchased Beta Bionics, Inc. common stock under the Nasdaq ticker BBNX between July 30, 2025, and February 24, 2026, inclusive, that November 3, 2026, is the deadline to seek appointment as lead plaintiff in a pending securities class action. The lawsuit alleges that defendants misrepresented the safety and performance of the company’s iLet Bionic Pancreas insulin pump and downplayed complaints filed with the FDA under a Form 483. According to the complaint, the device malfunctioned and delivered dangerously high insulin doses, causing hypoglycemic events; the complaints allegedly numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention. The lawsuit also alleges that Beta Bionics failed to implement meaningful corrective actions, causing investor losses when the alleged information reached the market. The class has not been certified, and investors may seek lead-plaintiff status, retain counsel, or remain absent class members. Rosen says eligible investors may participate through a contingency fee arrangement without upfront fees or costs.